DEERFIELD, Ill.--(BUSINESS WIRE)--OVATION Pharmaceuticals, Inc. announced today that it has signed a definitive agreement to enter into an exclusive collaboration with GTC Biotherapeutics in Framingham, Massachusetts, to develop and market ATryn® (antithrombin alfa) in the United States. OVATION will obtain the exclusive license to the U.S. rights to the product and will own certain assets, including the Biologics License Application, or BLA, following approval. The agreement calls for OVATION to make a series of potential payments to GTC for meeting regulatory, clinical, and sales milestones, with the initial payment due upon closing, which is subject to Hart-Scott-Rodino review and other conditions.
